Cargando…

Pathology and Classification of SCLC

SIMPLE SUMMARY: Small cell lung carcinoma (SCLC), is a high-grade neuroendocrine carcinoma defined by its aggressiveness, poor differentiation, and somber prognosis. This review highlights current pathological concepts including classification, immunohistochemistry features, and differential diagnos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raso, Maria Gabriela, Bota-Rabassedas, Neus, Wistuba, Ignacio I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919820/ https://www.ncbi.nlm.nih.gov/pubmed/33669241 http://dx.doi.org/10.3390/cancers13040820

Ejemplares similares

Cancer becomes wasteful: emerging roles of exosomes(†) in cell-fate determination
por: Wendler, Franz, et al.
Publicado: (2013)

FGF coordinates air sac development by activation of the EGF ligand Vein through the transcription factor PntP2
por: Cruz, Josefa, et al.
Publicado: (2015)

Author Correction: FGF coordinates air sac development by activation of the EGF ligand Vein through the transcription factor PntP2
por: Cruz, Josefa, et al.
Publicado: (2022)

What Are the Biomarkers for Immunotherapy in SCLC?
por: Longo, Vito, et al.
Publicado: (2021)

Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC
por: Zhang, Chenyue, et al.
Publicado: (2021)

Sonic Hedgehog in SCLC
por: Laukkanen, Mikko O., et al.
Publicado: (2015)

The evolving genomic classification of lung cancer
por: Shames, David S, et al.
Publicado: (2014)

Prophylactic cranial irradiation in SCLC
por: Suwinski, Rafal
Publicado: (2021)

What's New in SCLC? A Review
por: Oronsky, Bryan, et al.
Publicado: (2017)

Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy
por: Carpentier, Joséphine, et al.
Publicado: (2022)

The ISG15-specific protease USP18 regulates stability of PTEN
por: Mustachio, Lisa Maria, et al.
Publicado: (2016)

Use of osteoblast-derived matrix to assess the influence of collagen modifications on cancer cells
por: Bota-Rabassedas, Neus, et al.
Publicado: (2020)

Is transformed small cell lung cancer (SCLC) different from de novo SCLC?
por: Park, Cheol-Kyu, et al.
Publicado: (2019)

Promising Role of Circulating Tumor Cells in the Management of SCLC
por: De Luca, Antonella, et al.
Publicado: (2021)

Killing SCLC: insights into how to target a shapeshifting tumor
por: Sutherland, Kate D., et al.
Publicado: (2022)

Understanding SCLC heterogeneity and plasticity in cancer metastasis and chemotherapy resistance: Understanding SCLC heterogeneity and plasticity in metastasis and chemoresistance
por: Jin, Yujuan, et al.
Publicado: (2023)

Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
por: Brazel, Danielle, et al.
Publicado: (2023)

Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021)

Impact of Socioeconomic Factors on Overall Survival in SCLC
por: Roof, Logan, et al.
Publicado: (2022)

A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)
por: Oronsky, Bryan, et al.
Publicado: (2022)

Correction to: Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021)

Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?
por: Domvri, Kalliopi, et al.
Publicado: (2015)

Development and Validation of a Simplified Prognostic Score in SCLC
por: Negre, Elodie, et al.
Publicado: (2020)

Organoids as a Systems Platform for SCLC Brain Metastasis
por: Quaranta, Vito, et al.
Publicado: (2022)

Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models
por: Salgia, Ravi, et al.
Publicado: (2018)

Targeting DNA Replication Stress and DNA Double-Strand Break Repair for Optimizing SCLC Treatment
por: Bian, Xing, et al.
Publicado: (2019)

SCLC extensive disease – treatment guidance by extent or/and biology of response?
por: Eckert, Franziska, et al.
Publicado: (2008)

Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis
por: Wen, Pushuai, et al.
Publicado: (2018)

Racial and Other Healthcare Disparities in Patients With Extensive-Stage SCLC
por: Tapan, Umit, et al.
Publicado: (2020)

Subtype of SCLC Is an Intrinsic and Persistent Feature Through Systemic Treatment
por: Lo, Ying-Chun, et al.
Publicado: (2023)

Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)
por: Deneka, Alexander Y., et al.
Publicado: (2019)

Promoters of ASCL1‐ and NEUROD1‐dependent genes are specific targets of lurbinectedin in SCLC cells
por: Costanzo, Federico, et al.
Publicado: (2022)

Thy-1(+) Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis
por: Schliekelman, Mark J., et al.
Publicado: (2017)

Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors
por: Rojas, Frank, et al.
Publicado: (2022)

Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy
por: Chen, Hui-Zi, et al.
Publicado: (2021)

Survival, Chemotherapy and Chemosensitivity Predicted by CTC Cultured In Vitro of SCLC Patients
por: Ju, Lixia, et al.
Publicado: (2021)

Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy
por: Bütof, Rebecca, et al.
Publicado: (2017)

Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)
por: Saltos, Andreas, et al.
Publicado: (2020)

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
por: Ready, Neal, et al.
Publicado: (2018)

Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC
por: Smith, Jarrod T., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k049mr87vvv6ap22hqci555vbr